Figure 6 : mRNA levels of galectins and the receptors of Gal-9 in the lung and MLN tissues of PbANKA-infected mice with or without α-lactose treatment estimated using qRT-PCR.

From: Blockage of Galectin-receptor Interactions by α-lactose Exacerbates Plasmodium berghei-induced Pulmonary Immunopathology

Figure 6

(a) mRNA levels of Gal-1, Gal-3, Gal-8, and Gal-9; (b) mRNA levels of Tim-3, CD44, CD137, and PDI. Values are means from triplicate measurements, and data are presented as means ± SD; two independent experiments were performed with four mice per group. *P < 0.05; **P < 0.01; and ***P < 0.001, α-lactose-control, malarial mice on 5 days p.i., malarial mice treated with α-lactose on 5 days p.i., malarial mice on 7 days p.i., and malarial mice treated with α-lactose on 7 days p.i. vs. naive group; §, P < 0.05, malarial mice treated with α-lactose on 5 days p.i. and malarial mice treated with α-lactose on 7 days p.i. vs. α-lactose-control; #P < 0.05; ##P < 0.01; and ###P < 0.001, malarial mice treated with α-lactose on 5 days p.i. and malarial mice at 7 days p.i. vs. malarial mice on 5 days p.i.; Δ, P < 0.05; ΔΔ, P < 0.01; and ΔΔΔ, P < 0.001, malarial mice treated with α-lactose on 7 days p.i. vs. malarial treated with α-lactose on 5 days p.i.; ξ, P < 0.05; ξξ, P < 0.01; and ξξξ, P < 0.001, malarial mice treated with α-lactose on 7 days p.i. vs. malarial mice on 7 days p.i. REL: relative expression level.